• On July 8, 2026, Catalyst Pharmaceuticals held a virtual special shareholder meeting focused on its proposed merger with Angelini Pharma.
• Shareholders adopted the merger agreement, satisfying a closing condition for the transaction.
• An advisory resolution on merger-related executive compensation failed to pass, without affecting the merger’s completion conditions.
• A proposed adjournment resolution was not put to a vote because the merger agreement was adopted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-298739), on July 08, 2026, and is solely responsible for the information contained therein.